Role of Evogliptin for Intra‐Class Therapeutic Interchange in Patients With Type 2 Diabetes Mellitus: Subgroup Analysis From A Multi‐Center, Prospective, Observational Study ( REVISE Study)
Endocrinology, Diabetes & Metabolism · 2026
DOI: 10.1002/edm2.70270 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Endocrinology, Diabetes & Metabolism, 2026. Verfasst von Jie-Eun Lee und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, CHA Gangnam Medical Center, CHA University, Seoul, Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Hypoglycemic Agents, Piperazines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dong-A ST, Co. Ltd.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
While dipeptidyl peptidase‐4 (DPP‐4) inhibitors are commonly considered to have a class effect, emerging evidence suggests intra‐class heterogeneity in pharmacological properties. For patients who fail to achieve target glycemic levels with initial DPP‐4 inhibitors therapy, intra‐class therapeutic interchange may offer an alternative to dose escalation or add‐on therapy. This study evaluated the effectiveness of evogliptin, a novel and potent DPP‐4 inhibitor with a unique binding structure, as a strategy for therapeutic optimization. Materials and Methods This follow‐up analysis included patients with HbA1c ≥ 7.0% who had received metformin plus a DPP‐4 inhibitor other than evogliptin for at least 12 weeks and were subsequently switched to evogliptin. Changes in HbA1c and target achievement at 12 and 24 weeks were assessed according to the initial DPP‐4 inhibitors. Multivariable linear regression was performed to identify independent predictors of HbA1c reduction. Additional exploratory subgroup analyses were conducted according to demographic and baseline clinical characteristics.
Results
Among 770 patients in the effectiveness set, mean HbA1c decreased by −0.3% at 12 weeks and −0.5% at 24 weeks ( p < 0.0001 for both). In the sitagliptin group, reductions were −0.5% and −0.6%, respectively ( p < 0.0001). At 24 weeks, 25.8% and 50.5% of patients achieved HbA1c targets of < 6.5% and < 7.0%, respectively.
Conclusions
Intraclass therapeutic interchange (ICTI) to evogliptin from other DPP‐4 inhibitors was an effective and well‐tolerated strategy for optimizing glycemic control. These findings suggest that intra‐class therapeutic interchange could be an effective and well‐tolerated strategy for optimizing glycemic control in a clinical setting. However, given the observational nature of this study, further controlled studies are needed to confirm these findings against a comparator group. Trial Registration ClinicalTrials.gov NCT04326166
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology and Metabolism, Department of Internal Medicine, CHA Gangnam Medical Center, CHA University, Seoul, Korea.
- Department of Internal Medicine, Daejeon Eulji Medical Center, Eulji University, Daejeon, Korea.
- Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.
- Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.
- Division of Cardiology, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea.
ORCID-Profile: Jie-Eun Lee, Jun Hwa Hong, Jong Chul Won
Förderung
- Dong-A ST, Co. Ltd
Zitieren
APA
Lee, J. E., Hong, J. H., Yu, S. H., Baek, K. H., Yu, J., Lee, S. J., Kim, H. W., Park, K. S., Kim, J. H., Min, K., Lee, Y. H., Kim, K. S., Song, M. S., Kim, J. H., & Won, J. C. (2026). Role of Evogliptin for Intra‐Class Therapeutic Interchange in Patients With Type 2 Diabetes Mellitus: Subgroup Analysis From A Multi‐Center, Prospective, Observational Study ( REVISE Study). Endocrinology, Diabetes & Metabolism. https://doi.org/10.1002/edm2.70270
Vancouver
Lee JE, Hong JH, Yu SH, Baek KH, Yu J, Lee SJ, et al. Role of Evogliptin for Intra‐Class Therapeutic Interchange in Patients With Type 2 Diabetes Mellitus: Subgroup Analysis From A Multi‐Center, Prospective, Observational Study ( REVISE Study). Endocrinology, Diabetes & Metabolism. 2026. doi:10.1002/edm2.70270
BibTeX
@article{Lee2026,
author = {Lee, Jie-Eun and Hong, Jun Hwa and Yu, Sung Hoon and Baek, Ki-Hyun and Yu, JaeMyung and Lee, Seung Jin and Kim, Hyung-Wook and Park, Kang Seo and Kim, Jung Han and Min, KyungWan and Lee, Yong Hwan and Kim, Koon Soon and Song, Min Soo and Kim, Ji Hoon and Won, Jong Chul},
title = {Role of Evogliptin for Intra‐Class Therapeutic Interchange in Patients With Type 2 Diabetes Mellitus: Subgroup Analysis From A Multi‐Center, Prospective, Observational Study ( REVISE Study)},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2026},
doi = {10.1002/edm2.70270}
}
EUVIMED